On January 15, 2026, Sandip Kapadia, the Chief Financial Officer of Harmony Biosciences (NASDAQ: HRMY), sold 20,961 shares in an open-market transaction, fully exiting his direct equity ownership. This sale was reported in a SEC Form 4 filing. The transaction was valued based on a weighted average purchase price of $35.92 per share. This move marks a significant change in Kapadia’s financial involvement with the company.
Loading PerspectiveSplit analysis...
